AtomVie Global Radiopharma Forms Partnership with Jubilant Radiopharma for Enhanced Clinical Trial Services
On October 15, 2026, AtomVie Global Radiopharma, a premier contract development and manufacturing organization specializing in radiopharmaceuticals, announced a pivotal strategic partnership with Jubilant DraxImage Inc., operating as Jubilant Radiopharma. This collaboration aims to revolutionize the logistics and distribution aspects of clinical trials, ensuring efficient delivery of radiopharmaceutical products. The partnership is formalized under a comprehensive Logistics and Regulatory Services Agreement, which sets the stage for enhanced operational standards in the management of radiopharmaceuticals.
As radiopharmaceutical therapies gain prominence in the healthcare landscape, streamlining logistics processes becomes more crucial. Jubilant Radiopharma's robust U.S. pharmacy network will handle the critical processes of receiving, managing, and distributing AtomVie-manufactured radiopharmaceuticals, ensuring compliance with stringent regulatory requirements. This initiative seeks not only to expedite delivery to clinical sites but also to uphold the highest standards of product safety and quality.
"The growth within the radiopharmaceutical sector necessitates a strong and dependable logistics network. Collaborating with Jubilant Radiopharma highlights our commitment to maintaining these standards while expanding our clinical development support capabilities," stated Bruno Paquin, the CEO of AtomVie. He emphasized the importance of having a trusted partner like Jubilant, whose regulatory expertise and extensive distribution capabilities align seamlessly with AtomVie’s strategic goals to advance innovative therapies that transform patient outcomes.
Echoing these sentiments, Harsher Singh, CEO of Jubilant Radiopharma, remarked, "Our alliance reflects a mutual dedication to enhancing the delivery and accessibility of radiopharmaceuticals throughout North America. With our established infrastructure and expertise, we are well-equipped to support the evolving needs of clinical trials and product commercialization during this transformative era in nuclear medicine."
This collaboration will significantly boost AtomVie's integrated service offerings by leveraging Jubilant Radiopharma's extensive distribution capabilities. The shared expertise in regulatory compliance, logistics management, and therapeutic dispensing positions both companies to effectively navigate the challenges of radiopharmaceutical development and commercialization.
AtomVie Global Radiopharma is headquartered in Hamilton, Ontario, and operates from a cutting-edge facility designed to support the development and manufacturing of radiotherapeutic agents. With a focus on comprehensive solutions, AtomVie integrates process development, GMP manufacturing, regulatory support, and global distribution to meet the needs of pharmaceutical and biotechnology clients aiming to innovate in the field of radiopharmaceuticals.
Established as a major player in the radiopharmaceutical industry, Jubilant Radiopharma boasts one of the largest radiopharmacy networks in the United States, dedicated to enhancing patient access to diagnostic and therapeutic products. With over 70 years of experience in the nuclear medicine sector, Jubilant is committed to advancing patient care through innovative solutions.
As AtomVie and Jubilant Radiopharma join forces, the radiopharmaceutical community can look forward to increased efficiencies in clinical trial logistics and expanded access to life-saving therapies, heralding a new chapter in medical innovation. Both companies remain steadfast in their mission to improve lives through the development and distribution of high-quality nuclear medicine products. For more details about their collaborative efforts and service offerings, interested parties are encouraged to visit AtomVie’s website and Jubilant Radiopharma’s website.
As radiopharmaceutical therapies gain prominence in the healthcare landscape, streamlining logistics processes becomes more crucial. Jubilant Radiopharma's robust U.S. pharmacy network will handle the critical processes of receiving, managing, and distributing AtomVie-manufactured radiopharmaceuticals, ensuring compliance with stringent regulatory requirements. This initiative seeks not only to expedite delivery to clinical sites but also to uphold the highest standards of product safety and quality.
"The growth within the radiopharmaceutical sector necessitates a strong and dependable logistics network. Collaborating with Jubilant Radiopharma highlights our commitment to maintaining these standards while expanding our clinical development support capabilities," stated Bruno Paquin, the CEO of AtomVie. He emphasized the importance of having a trusted partner like Jubilant, whose regulatory expertise and extensive distribution capabilities align seamlessly with AtomVie’s strategic goals to advance innovative therapies that transform patient outcomes.
Echoing these sentiments, Harsher Singh, CEO of Jubilant Radiopharma, remarked, "Our alliance reflects a mutual dedication to enhancing the delivery and accessibility of radiopharmaceuticals throughout North America. With our established infrastructure and expertise, we are well-equipped to support the evolving needs of clinical trials and product commercialization during this transformative era in nuclear medicine."
This collaboration will significantly boost AtomVie's integrated service offerings by leveraging Jubilant Radiopharma's extensive distribution capabilities. The shared expertise in regulatory compliance, logistics management, and therapeutic dispensing positions both companies to effectively navigate the challenges of radiopharmaceutical development and commercialization.
AtomVie Global Radiopharma is headquartered in Hamilton, Ontario, and operates from a cutting-edge facility designed to support the development and manufacturing of radiotherapeutic agents. With a focus on comprehensive solutions, AtomVie integrates process development, GMP manufacturing, regulatory support, and global distribution to meet the needs of pharmaceutical and biotechnology clients aiming to innovate in the field of radiopharmaceuticals.
Established as a major player in the radiopharmaceutical industry, Jubilant Radiopharma boasts one of the largest radiopharmacy networks in the United States, dedicated to enhancing patient access to diagnostic and therapeutic products. With over 70 years of experience in the nuclear medicine sector, Jubilant is committed to advancing patient care through innovative solutions.
As AtomVie and Jubilant Radiopharma join forces, the radiopharmaceutical community can look forward to increased efficiencies in clinical trial logistics and expanded access to life-saving therapies, heralding a new chapter in medical innovation. Both companies remain steadfast in their mission to improve lives through the development and distribution of high-quality nuclear medicine products. For more details about their collaborative efforts and service offerings, interested parties are encouraged to visit AtomVie’s website and Jubilant Radiopharma’s website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.